S E Kjeldsen

TL;DR: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study as discussed by the authors is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality.

TL;DR: Findings of an apparent interaction between atorvastatin and an amlodipine-based regimen in the prevention of CHD events are of borderline significance, and hence generate an hypothesis that merits independent evaluation in other trials.

TL;DR: In the large diabetic subgroup in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, the benefits of amlodipine-based treatment, compared with atenolol- based treatment, on the incidence of total cardiovascular events and procedures was significant and similar to that observed in the total trial population.

TL;DR: Patients with no significant decrease and patients with regression of ECG LVH had stepwise greater absolute decreases in LV mass and were more likely to decrease LV mass, even after adjusting for possible effects of baseline and change in systolic and diastolic pressures.

TL;DR: Compared with a conventional diuretic/β-blocker-based antihypertensive regimen, there were additional 25% reductions in stroke in the diltiazem-treated patients with blood pressure or pulse pressure greater than the medians, and an increase in myocardial infarction in those with heart rate less than the median.